{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:22:08Z","timestamp":1770337328039,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s00277-022-05041-0","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T06:02:46Z","timestamp":1668664966000},"page":"407-412","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Allogeneic stem cell transplantation in patients with a prior history of prostate cancer"],"prefix":"10.1007","volume":"102","author":[{"given":"Raffaele","family":"Palmieri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert B.","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5525-3748","authenticated-orcid":false,"given":"Kristine","family":"Doney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,17]]},"reference":[{"issue":"11","key":"5041_CR1","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1016\/j.bbmt.2015.07.032","volume":"21","author":"NS Majhail","year":"2015","unstructured":"Majhail NS, Farnia SH, Carpenter PA, Champlin RE, Crawford S, Marks DI et al (2015) Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 21(11):1863\u20131869. https:\/\/doi.org\/10.1016\/j.bbmt.2015.07.032","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"5041_CR2","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1182\/blood-2017-03-772368","volume":"130","author":"L Muffly","year":"2017","unstructured":"Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K et al (2017) Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood 130(9):1156\u20131164. https:\/\/doi.org\/10.1182\/blood-2017-03-772368","journal-title":"Blood"},{"issue":"9","key":"5041_CR3","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1182\/blood-2017-07-795948","volume":"130","author":"T Zuckerman","year":"2017","unstructured":"Zuckerman T (2017) Allogeneic transplant: does age still matter? Blood 130(9):1079\u20131080. https:\/\/doi.org\/10.1182\/blood-2017-07-795948","journal-title":"Blood"},{"issue":"1","key":"5041_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/bmt.2015.203","volume":"51","author":"MJ Ehrhardt","year":"2016","unstructured":"Ehrhardt MJ, Brazauskas R, He W, Rizzo JD (2016) Shaw BE 2016 Survival of patients who develop solid tumors following hematopoietic stem cell transplantation. Bone Marrow Transplant 51(1):83\u201388. https:\/\/doi.org\/10.1038\/bmt.2015.203","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"5041_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1053\/j.seminhematol.2011.10.013","volume":"49","author":"G Socie","year":"2012","unstructured":"Socie G, Rizzo JD (2012) Second solid tumors: screening and management guidelines in long-term survivors after allogeneic stem cell transplantation. Semin Hematol 49(1):4\u20139. https:\/\/doi.org\/10.1053\/j.seminhematol.2011.10.013","journal-title":"Semin Hematol"},{"issue":"8","key":"5041_CR6","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8):2912\u20132919. https:\/\/doi.org\/10.1182\/blood-2005-05-2004","journal-title":"Blood"},{"key":"5041_CR7","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1182\/asheducation-2010.1.237","volume":"2010","author":"ML Sorror","year":"2010","unstructured":"Sorror ML (2010) Comorbidities and hematopoietic cell transplantation outcomes. Hematology Am Soc Hematol Educ Program 2010:237\u2013247. https:\/\/doi.org\/10.1182\/asheducation-2010.1.237","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"5041_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE (2021) Jemal A 2021 Cancer statistics. CA Cancer J Clin 71(1):7\u201333. https:\/\/doi.org\/10.3322\/caac.21654","journal-title":"CA Cancer J Clin"},{"issue":"13","key":"5041_CR9","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1002\/cncr.31549","volume":"124","author":"S Negoita","year":"2018","unstructured":"Negoita S, Feuer EJ, Mariotto A, Cronin KA, Petkov VI, Hussey SK et al (2018) Annual report to the nation on the status of cancer, part II: recent changes in prostate cancer trends and disease characteristics. Cancer 124(13):2801\u20132814. https:\/\/doi.org\/10.1002\/cncr.31549","journal-title":"Cancer"},{"issue":"7","key":"5041_CR10","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1001\/jamaoncol.2015.6310","volume":"2","author":"R Etzioni","year":"2016","unstructured":"Etzioni R, Gulati R (2016) Recent trends in PSA testing and prostate cancer incidence: a look at context. JAMA Oncol 2(7):955\u2013956. https:\/\/doi.org\/10.1001\/jamaoncol.2015.6310","journal-title":"JAMA Oncol"},{"issue":"7","key":"5041_CR11","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1001\/jamainternmed.2017.0340","volume":"177","author":"SA Fedewa","year":"2017","unstructured":"Fedewa SA, Ward EM, Brawley O, Jemal A (2017) Recent patterns of prostate-specific antigen testing for prostate cancer screening in the United States. JAMA Intern Med 177(7):1040\u20131042. https:\/\/doi.org\/10.1001\/jamainternmed.2017.0340","journal-title":"JAMA Intern Med"},{"issue":"6","key":"5041_CR12","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.eururo.2016.11.006","volume":"71","author":"WS Ham","year":"2017","unstructured":"Ham WS, Chalfin HJ, Feng Z, Trock BJ, Epstein JI, Cheung C et al (2017) New prostate cancer grading system predicts long-term survival following surgery for Gleason score 8\u201310 prostate cancer. Eur Urol 71(6):907\u2013912. https:\/\/doi.org\/10.1016\/j.eururo.2016.11.006","journal-title":"Eur Urol"},{"issue":"5","key":"5041_CR13","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY et al (2019) Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 20(5):686\u2013700. https:\/\/doi.org\/10.1016\/S1470-2045(19)30082-8","journal-title":"Lancet Oncol"},{"issue":"5","key":"5041_CR14","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1182\/blood-2008-05-158782","volume":"113","author":"JD Rizzo","year":"2009","unstructured":"Rizzo JD, Curtis RE, Socie G, Sobocinski KA, Gilbert E, Landgren O et al (2009) Solid cancers after allogeneic hematopoietic cell transplantation. Blood 113(5):1175\u20131183. https:\/\/doi.org\/10.1182\/blood-2008-05-158782","journal-title":"Blood"},{"issue":"2","key":"5041_CR15","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.transproceed.2004.12.127","volume":"37","author":"ES Woodle","year":"2005","unstructured":"Woodle ES, Gupta M, Buell JF, Neff GW, Gross TG, First MR et al (2005) Prostate cancer prior to solid organ transplantation: the Israel Penn International Transplant Tumor Registry experience. Transplant Proc 37(2):958\u2013959. https:\/\/doi.org\/10.1016\/j.transproceed.2004.12.127","journal-title":"Transplant Proc"},{"issue":"1","key":"5041_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.suc.2018.09.004","volume":"99","author":"AP Rossi","year":"2019","unstructured":"Rossi AP, Klein CL (2019) Posttransplant malignancy. Surg Clin North Am 99(1):49\u201364. https:\/\/doi.org\/10.1016\/j.suc.2018.09.004","journal-title":"Surg Clin North Am"},{"issue":"12","key":"5041_CR17","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1111\/j.1600-6143.2008.02430.x","volume":"8","author":"K Chamie","year":"2008","unstructured":"Chamie K, Ghosh PM, Koppie TM, Romero V, Troppmann C (2008) deVere White RW 2008 The effect of sirolimus on prostate-specific antigen (PSA) levels in male renal transplant recipients without prostate cancer. Am J Transplant 8(12):2668\u20132673. https:\/\/doi.org\/10.1111\/j.1600-6143.2008.02430.x","journal-title":"Am J Transplant"},{"issue":"7","key":"5041_CR18","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1158\/0008-5472.CAN-04-3137","volume":"65","author":"L Wu","year":"2005","unstructured":"Wu L, Birle DC, Tannock IF (2005) Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 65(7):2825\u20132831. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-3137","journal-title":"Cancer Res"},{"issue":"6719","key":"5041_CR19","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/17401","volume":"397","author":"M Hojo","year":"1999","unstructured":"Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M et al (1999) Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397(6719):530\u2013534. https:\/\/doi.org\/10.1038\/17401","journal-title":"Nature"},{"issue":"7","key":"5041_CR20","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1097\/01.tp.0000184006.43152.8d","volume":"80","author":"HM Kauffman","year":"2005","unstructured":"Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD (2005) Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80(7):883\u2013889. https:\/\/doi.org\/10.1097\/01.tp.0000184006.43152.8d","journal-title":"Transplantation"},{"key":"5041_CR21","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ctrv.2017.03.001","volume":"55","author":"M Del Re","year":"2017","unstructured":"Del Re M, Fogli S, Derosa L, Massari F, De Souza P, Crucitta S et al (2017) The role of drug-drug interactions in prostate cancer treatment: focus on abiraterone acetate\/prednisone and enzalutamide. Cancer Treat Rev 55:71\u201382. https:\/\/doi.org\/10.1016\/j.ctrv.2017.03.001","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"5041_CR22","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s40262-016-0403-6","volume":"55","author":"GE Benoist","year":"2016","unstructured":"Benoist GE, Hendriks RJ, Mulders PF, Gerritsen WR, Somford DM, Schalken JA et al (2016) Pharmacokinetic aspects of the two novel oral drugs used for metastatic castration-resistant prostate cancer: abiraterone acetate and enzalutamide. Clin Pharmacokinet 55(11):1369\u20131380. https:\/\/doi.org\/10.1007\/s40262-016-0403-6","journal-title":"Clin Pharmacokinet"},{"key":"5041_CR23","doi-asserted-by":"publisher","unstructured":"Fay EK, Graff JN (2020) Immunotherapy in prostate cancer. Cancers (Basel) 12(7).\u00a0https:\/\/doi.org\/10.3390\/cancers12071752","DOI":"10.3390\/cancers12071752"},{"key":"5041_CR24","doi-asserted-by":"publisher","first-page":"562315","DOI":"10.3389\/fonc.2021.562315","volume":"11","author":"S Chen","year":"2021","unstructured":"Chen S, Zhang Z, Zheng X, Tao H, Zhang S, Ma J (2021) Response efficacy of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. Front Oncol 11:562315. https:\/\/doi.org\/10.3389\/fonc.2021.562315","journal-title":"Front Oncol"},{"issue":"1","key":"5041_CR25","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.bbmt.2018.08.028","volume":"25","author":"A Ijaz","year":"2019","unstructured":"Ijaz A, Khan AY, Malik SU, Faridi W, Fraz MA, Usman M et al (2019) Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Biol Blood Marrow Transplant 25(1):94\u201399. https:\/\/doi.org\/10.1016\/j.bbmt.2018.08.028","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"5041_CR26","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1182\/blood-2015-10-672071","volume":"127","author":"M Mielcarek","year":"2016","unstructured":"Mielcarek M, Furlong T, O\u2019Donnell PV, Storer BE, McCune JS, Storb R et al (2016) Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. Blood 127(11):1502\u20131508. https:\/\/doi.org\/10.1182\/blood-2015-10-672071","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-05041-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-05041-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-05041-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T09:06:31Z","timestamp":1675155991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-05041-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,17]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["5041"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-05041-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,17]]},"assertion":[{"value":"9 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval was obtained from the Institutional Review Board of the Fred Hutchinson Cancer Research Center. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all patients and donors included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}